Tigatuzumab Biosimilar: Harnessing DR5 for Targeted Cancer Therapy Tigatuzumab is a monoclonal antibody targeting death receptor 5 (DR5), a member of the … read more 17th Dec 2025 Shanza Riaz
Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics Enavatuzumab is a monoclonal antibody targeting TWEAK receptor (TWEAKR, also known as F … read more 13th Jan 2025
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements Alemtuzumab is a monoclonal antibody targeting CD52, a glycoprotein highly expressed on … read more 13th Jan 2025